The present review suggests that upregulating the formation of AA, a putative endogenous GPR109A agonist, is a compensatory (adaptive) response aimed at attenuating the development of cognitive impairment in schizophrenia, MCI, and AD (Figure 3). Here, HCAR2 is linked to Alzheimer disease.